Prognose

Für dieses Unternehmen liegen uns keine Analysten-Daten vor.

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis (ALS), Alzheimer's, and Parkinson's disease, announces that it will present at Biotech Showcase 2025, an event expected to include over 3,200 healthcare professionals with more than 1,200 investors. The event will be held at the Hilton Hotel in Union Square, San Francisco during the J.P.» Mehr auf globenewswire.com
Klotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco
Company to present at 3:00 p.m. PT on Tuesday, January 14, at the Hilton San Francisco Union Square New York, NY, January 8, 2025 – PRISM MediaWire – Klotho Neurosciences, Inc.» Mehr auf prismmediawire.com
Dr. Merit Cudkowicz, Renowned ALS Expert at Massachusetts General Hospital (MGH), Joins Klotho Neurosciences' Scientific Advisory Board
Klotho Neurosciences, Inc. continues to strengthen its advisory teams with recent new additions of Neuroscience and Big Pharma leaders to Scientific Advisory Board and Board of Directors New York, NY, December 9, 2024 – PRISM MediaWire – Klotho Neurosciences, Inc.» Mehr auf prismmediawire.com

Im letzten Quartal hatte KLOTHO NEUROSCIENCES INC. einen Umsatz von 0,00€ und ein Nettoeinkommen von −1,99 Mio€